Recursion Pharmaceuticals RXRX · NASDAQ
$3.74 -2.60% (-$0.10)
Summary
44 / 100 · Bulios Score
What speaks for it
- Revenue grew by 23% a year over the last 3 years.
- It holds more cash than debt: $545.7M against $61.9M.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 45% this fiscal year.
- It missed profit estimates 5 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 85% a year over 5 years. Over the last 3 years it grew by 23% a year. For the next fiscal year analysts expect revenue to fall by 45%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $518.9M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $5.3 is 42% above today's price. 40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License and Service 99%
- Grant 0.6%
By region
- UNITED STATES 100%
License and Service brings in 99% of revenue.
Segments in detail